Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method

Eur Ann Otorhinolaryngol Head Neck Dis. 2023 Nov 28:S1879-7296(23)00158-8. doi: 10.1016/j.anorl.2023.11.006. Online ahead of print.

Abstract

Objective: To determine the indications for radiotherapy in salivary gland cancer and to specify the modalities and target radiation volumes.

Material and methods: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.

Results: Postoperatively, radiotherapy to the primary tumor site±to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk>10% of locoregional recurrence): T3-T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered.

Conclusion: Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors.

Keywords: Hadrontherapy; Radiotherapy; Salivary gland cancer.

Publication types

  • Practice Guideline